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Introduction {#sec005}
============

Esophageal carcinoma (EC) is the most aggressive malignant tumor of the gastrointestinal tract and the eighth most commonly occurring cancer in the world \[[@pone.0159140.ref001]\]. It has been well recognized that the development of EC involves multiple factors in a multistage process \[[@pone.0159140.ref002]\]. Alcohol, tobacco, nutritional deficiencies, infectious agents, etc. were confirmed to have a relationship to esophageal carcinogenesis \[[@pone.0159140.ref003]\]. However, many physical, chemical and biological factors related to EC remain unknown.

Human papillomavirus (HPV) infections, especially high-risk types 16 and 18, have recently been reported as a possible risk factor for EC. However, direct evidence of this relationship has been lacking, and results of those studies were not consistent. This study aimed to conduct a meta-analysis, and systematic review of literature to determine whether an association exists between HPV type 16 and 18 infection and EC.

Materials and Methods {#sec006}
=====================

Data Sources {#sec007}
------------

A literature search was performed from 1982 to 2014 using PUBMED and CNKI databases without restrictions, and the following search terms were used: (human papillomavirus, HPV) and (esophageal, esophagus) and (cancer, carcinoma, tumor). Moreover, reference lists were reviewed to search for relevant studies. This systematic review was planned and reported in adherence to the standards of quality for reporting systematic reviews.

Inclusion and Validity Criteria {#sec008}
-------------------------------

All searches were performed by reviewing articles and abstracts cited in the published systematic reviews and case-control studies. Inclusion criteria were as follows: (1) prospective case-control studies, (2) EC diagnosed by pathology, (3) Control group obtained from esophageal epithelial tissues of normal individuals (screening) or normal marginal tissues of EC.

Exclusion criteria {#sec009}
------------------

Exclusion criteria included the following: reports of poor quality, duplicate reports, inadequate information, unclear data descriptions or samples were removed, sample size less than 20, and abstracts.

Quality evaluation {#sec010}
------------------

The Jadad scoring method was used to evaluate several aspects of the quality of the study. Three independent researchers extracted data, blindly evaluated the quality of the literature, and analyzed the data including withdrawals and dropouts \[[@pone.0159140.ref004]\]. If there were differences of opinion, the cases were discussed until consensus was achieved.

Statistical Analysis {#sec011}
--------------------

A heterogeneity test was used to select the method of data combination in the systematic review. The Cochrane's Q-test was performed and I^2^ statistics were obtained, using a predefined significance threshold of 0.05.If *P*≥0.05, it was considered that there was no heterogeneity between studies; and a fixed effects model (FEM) was used for the analysis. If *P*\<0.05, it was considered that heterogeneity existed between studies; and a random effects model (REM) was used after correction for analysis. If a null hypothesis, which represents that there was no heterogeneity among each study, was accepted, the Mantel-Haenszel fixed-effects model was used to calculate the combined odds ratio (OR) with 95% confidence intervals (CI) and the Forest Plot. If the null hypothesis was rejected, REM was used to calculate the combined OR with 95% CI and the Forest Plot. To detect publication bias, the asymmetry of standard error--based funnel plots was examined using the linear regression method, as suggested by Egger *et al*. \[[@pone.0159140.ref005]\]. The Stata10.0 software (Stata Corporation, College Station, Texas) was used for the statistical analysis in this study.

Subgroup analyses {#sec012}
-----------------

EC incidence in subgroups were stratified and analyzed according to various geographical areas, the control group selection method, and various HPV detection methods.

Results {#sec013}
=======

Search Results {#sec014}
--------------

A total of 297 articles were identified by using the search criteria, and these studies were carried out from 1982 to 2014. All studies were obtained from published literature ([Fig 1](#pone.0159140.g001){ref-type="fig"}). Nine countries including China, Iran, Italy, Greece, Egypt, Sweden, Japan, France and Mexico were involved in the case-control studies. A total of 33 case-control studies were selected for analysis. There was no statistical significance in factors such as gender or age between the two groups. The PRISMA checklist is shown in [S1 PRISMA Checklist](#pone.0159140.s001){ref-type="supplementary-material"}.

![Selection of studies for inclusion in the meta-analysis.](pone.0159140.g001){#pone.0159140.g001}

Information of articles {#sec015}
-----------------------

Detailed steps of the literature search are shown in [Fig 1](#pone.0159140.g001){ref-type="fig"}. The inclusion and exclusion of case-control studies for this systematic review are shown in the flow chart. Briefly, 33 articles matched the standard \[[@pone.0159140.ref006]--[@pone.0159140.ref038]\]. Among the 2,430 cases in the EC group, 1,131 were HPV positive (46.54%); while among the 3,621 cases in the control group, 977 were HPV positive (26.98%). In the control group, 14 samples came from adjacent normal tissues of gastrointestinal cancers, while 19 samples came from normal esophageal specimens. These samples were obtained during the esophageal cancer screening of healthy people living in areas of high incidence of esophageal cancer ([Table 1](#pone.0159140.t001){ref-type="table"}).

10.1371/journal.pone.0159140.t001

###### Characteristics of the 33 case-control studies included in the meta-analysis.

![](pone.0159140.t001){#pone.0159140.t001g}

  Literature sources    HPV(+)/   HPV(+)/   Area              Incidence   Detection Method   Control selection   HPV types
  --------------------- --------- --------- ----------------- ----------- ------------------ ------------------- -----------------------
  Li Y, 1991            12/24     9/24      China             Unclear     ISH                Adjacent-normal     16
  Han C, 1996           22/90     6/121     China             High        ELISA              True-normal         16
  Ren ZHP, 1996         35/52     2/30      China             Lower       IHC                True-normal         16,18
  Wang XJ, 1998         20/40     36/58     China             High        ISH                True-normal         16
  Lu LC, 1999           15/55     43/55     China             High        ISH                Adjacent-normal     18
  Cao BW 2005           207/265   203/357   China             High        PCR                True-normal         16, 18
  Liu J, 2000           44/60     23/56     China             High        IHC                True-normal         16,18
  Yu DH, 2000           78/112    42520     China             Lower       IHC                True-normal         16,18
  Kuang ZS, 2000        23/56     4/56      China             High        PCR                Adjacent-normal     16,18
  Sun LB, 2001          42542     42390     China             Lower       PCR-RT             Adjacent-normal     16
  Shen ZY, 2002         115/176   105/176   China             High        PCR                Adjacent-normal     6, 11, 16, 18
  Xu WG, 2003           28/40     10/50     China             Unclear     ISH                True-normal         16
  Zhou XB, 2003         31/48     42605     China             High        PCR                Adjacent-normal     16
  Xu CL, 2004           16/18     126/183   China             Lower       IHC                Adjacent-normal     16
  Lu HS, 2004           3/40      13/39     China             Lower       IHC                Adjacent-normal     16
  Lu XM, 2004           55/104    41/104    China             High        PCR                Adjacent-normal     16
  Chen J, 2004          14/30     7/60      China             Lower       PCR                True-normal         16
  Jiang HY, 2005        48/65     11/65     China             Lower       IHC                Adjacent-normal     16,18
  Kamangar F, 2006      33/99     106/381   China             High        ELISA              True-normal         16,18,73
  Zhou SM, 2009         26/82     10/80     China             High        PCR                Adjacent-normal     16
  Guo F,2012            93/300    61/900    China             High        PCR                True-normal         16,18,58
  Bahnassy AA, 2005     27/50     12/50     Egypt             Unclear     PCR                Adjacent-normal     16,18,11
  Benamouzig R, 1992    42502     42393     France            Unclear     ISH                True-normal         6, 11, 16, 18,31, 33,
  Lyronis, 2008         17/30     42548     Greece            Unclear     PCR                True-normal         16,18
  Farhadi M, 2005       14/38     5/38      Iran              High        PCR                True-normal         L1,18
  Far AE, 2007          33/140    12/140    Iranian           Unclear     PCR                Adjacent-normal     16.18.31.33
  Astori G, 2001        42568     42476     Italy             High        PCR                Adjacent-normal     16
  Tornesello ML, 2009   12/56     42609     Italy             Unclear     PCR                True-normal         6,16,8, 15, 20,25
  Khurshid A, 1998      17/27     42441     Japan             Unclear     PCR                True-normal         16,18,33
  Kawaguchi H, 2000     42721     25/58     Japan and China   Unclear     PCR                True-normal         16/18
  Dąbrowski A, 2012     28/56     4/35      Lublin            Unclear     PCR                True-normal         16,18
  Acevedo, NE, 2004     15/17     42544     México            Unclear     PCR                True-normal         16,11
  Lagergren J, 1999     20/193    61/302    Sweden            Unclear     ELISA              True-normal         16,18

Lower: lower incidence of esophageal carcinoma (EC); Higher: higher incidence of EC; PCR: polymerase chain reaction; IHC: immunohistochemistry; ISH: in situ hybridization; ELISA: enzyme-linked immunosorbent assay. Adjacent-normal: the control group was obtained from the normal marginal tissue of EC during surgery. True-normal: controls were obtained from the normal esophageal epithelial tissue.

Heterogeneity test {#sec016}
------------------

Thirty-three tests for heterogeneity (*i* = 94.78, *P*\<0.001) revealed that there was heterogeneity between studies and between subgroups. Therefore, overall and subgroup analyses were corrected using REM; and the method of DerSimonian-Laird as used to merge data, and calculate ORs and 95% CIs. Egger's regression analysis was used to more objectively evaluate publication bias ([Table 2](#pone.0159140.t002){ref-type="table"}).

10.1371/journal.pone.0159140.t002

###### Quality assessment and subgroup analysis of HPV infection and esophageal carcinoma.

![](pone.0159140.t002){#pone.0159140.t002g}

  Group       No. of Studies   Heterogeneity of ORs   Model used   Egger\'s test                             
  ----------- ---------------- ---------------------- ------------ -------------------- ----- ------ ------- ---------------
  ALL         33               78.4                   \<0.001      1.45 (1.34--1.57)    REM   2.05   0.058   -0.01--2.64
  Area                                                                                                       
  High        13               31.93 (11)             \<0.001      2.96 (2.01--4.34)    REM   1.71   0.173   -0.61--3.03
  Lower       7                56.21 (7)              \<0.001      3.57 (1.15--11.12)   REM   0.37   0.443   -2.90--5.68
  China       21               31.93 (12)             \<0.001      2.96 (2.01--4.35)    REM   1.69   0.130   -0.46--3.33
  Non-China   12               56.21 (8)              \<0.001      3.57 (1.15--11.13)   REM   0.37   0.558   -4.35--2.49
  Asia        24               31.93 (13)             \<0.001      2.96 (2.01--4.36)    REM   1.73   0.090   -0.24--0.017
  Non-Asia    9                56.21 (9)              \<0.001      3.57 (1.15--11.14)   REM   0.37   0.091   -0.67--7.04
  Method                                                                                                     
  PCR         18               20.39 (10)             0.030        3.49 (2.49--4.90)    REM   1.25   0.012   0.91--2.38
  IHC         6                38.43 (5)              \<0.001      4.76 (1.36--16.63)   REM   0      0.659   -5.02--7.10
   ELSIA      4                20.02 (2)              \<0.001      0.90 (0.13--6.48)    REM   0      0.666   -74.37--81.47
  ISH         5                19.03(2)               \<0.001      0.90 (0.15--6.42)    REM   0      0.254   -4.30--11.12
  Self                                                                                                       
  Self        14               56.09 (9)              \<0.001      2.18 (1.02--4.66)    REM   0.89   0.200   -0.80--3.41
  NO          19               36.69 (9)              \<0.001      4.58 (2.69--7.80)    REM   2.33   0.102   -0.32--3.22

PCR: polymerase chain reaction; IHC: immunohistochemistry; ELISA: enzyme-linked immunosorbent assay; ISH: in situ hybridization; REM: random effects model; OR: odds ratio; CI: confidence interval.

The relationship of HPV types 16 and 18 and EC {#sec017}
----------------------------------------------

Among the 33 studies, infection rate in the EC group was 46.5%, while infection rate in the control group was 27.0%. Heterogeneity test revealed that there was heterogeneity (*χ*^*2*^ = 78.4, *P*\<0.001) with a *P*\<0.05 for the *Q*-test. A REM analysis was applied. The combined effect of these test results revealed an association between HPV infection and EC. From the independent OR and synthetic OR of the 33 researches, HPV infection was found to be closely associated with EC. The merger OR value was 1.62; 95% CI of 1.33--1.981.57, [Fig 2](#pone.0159140.g002){ref-type="fig"}. The accuracy of each study as argument, with OR/SE as the dependent variable, had a 95% CI of -0.0111784--2.63736 (*P* = 0.058). Therefore, there was no significant bias in the publications, there was no substantive effect on the synthetic OR, and the conclusion was reliable ([Fig 3](#pone.0159140.g003){ref-type="fig"}).

![Individual trial and overall risk ratios of the association between HPV (types 16 and 18) infection and esophageal carcinoma.](pone.0159140.g002){#pone.0159140.g002}

![Begg's funnel plot on studies of HPV infection and esophageal carcinoma.](pone.0159140.g003){#pone.0159140.g003}

Subgroup systematic review {#sec018}
--------------------------

EC incidence in subgroups were stratified and analyzed according to various geographical areas ([Fig 4A--4C](#pone.0159140.g004){ref-type="fig"}), the control group selection method ([Fig 5](#pone.0159140.g005){ref-type="fig"}), and various HPV detection methods.

![Individual trial and overall risk ratios of relationships between HPV infection and esophageal carcinoma in various geographical areas.\
4A: China, 4B: non-China and 4C: Asia/non-Asia.](pone.0159140.g004){#pone.0159140.g004}

![Individual trial and overall risk ratios of relationships between HPV infection and esophageal carcinoma compared to various controls.](pone.0159140.g005){#pone.0159140.g005}

There were 21 case-control studies in China. The merger OR value was 1.62 (95% CI: 1.26--2.07) including high incidence areas for EC such as the Taihang, Qinling and Dabie mountain ranges, as well as the northeast of Sichuan, east of Xinjiang, east of Fujian and east of Guangdong provinces. No publication bias (Egger's test, *P*\>0.05) was found, indicating that the results had good reliability. In other regions (outside China) such as Egypt, France, Greece, Iran and other countries, merger OR value was 1.80 (95% CI: 1.16--2.79); and there was also no publication bias (Egger's test, *P*\>0.05). In Asian countries such as China, Japan and India, the merger OR value was 1.63 (95% CI: 1.29--2.04); and there was no publication bias (Egger's test, *P*\>0.05). In non-Asian countries such as Egypt, France, Greece, Iran, Italy, Mexico and Sweden, merger OR value was 1.64 (95% CI: 1.01--2.67); and there was no publication bias (Egger's test, *P*\>0.05). In addition, results were same in both high risk and low risk areas. In high risk areas, merger OR value was 1.29 (95% CI: 1.05--1.59); while in low risk areas, merger OR value was 2.06 (95% CI: 1.08--3.94). ([Fig 4A--4C](#pone.0159140.g004){ref-type="fig"})

In the control patient group (healthy individuals), merger OR value was 1.41 (95% CI: 1.06--1.89); while in the control tissue group (normal tissues from EC patients), merger OR value was 1.82 (95% CI: 1.36--2.42, [Fig 5](#pone.0159140.g005){ref-type="fig"}).

Various HPV detection methods were summarized and analyzed: 18 cases were detected by PCR, 6 cases were detected by ISH, 6 cases were detected by IHC, and 3 cases were detected by ELISA. In the PCR group, merger OR value was 1.61 (95% CI: 1.33--1.95); in the ISH group, merger OR value was 1.21 (95% CI: 0.62--2.36); and in the IHC group, merger OR value was 1.69 (95% CI: 0.96--2.96). An opposite result was acquired in the ELISA group, where the merger OR value was 1.28 (95% CI: 0.54--3.04; [Fig 6A--6D](#pone.0159140.g006){ref-type="fig"}).

![Individual Trial and Overall Risk Ratios of Relationships between HPV Infection and EC using Various Detection Methods.\
(6A:PCR, 6B IHC, 6C:ISH, 6D:ELISA).](pone.0159140.g006){#pone.0159140.g006}

Discussion {#sec019}
==========

EC is the fifth most common cancer in developing countries, and the eighth most common cancer worldwide\[[@pone.0159140.ref039]\]. Areas of high prevalence for EC are mainly located in developing countries, and there are obvious regional differences. \[[@pone.0159140.ref040]\] The world's highest areas of incidence are located in Asia, which is called, the \"EC belt\" \[[@pone.0159140.ref041]\]. ECs vary greatly by geographic distribution, in which there is a higher incidence in China, America and the eastern Himalayas \[[@pone.0159140.ref042]\]. However, the incidence of esophageal cancer is low in developed Western countries.

There are several proposed risk factors for EC including eating habits, tobacco, alcohol, pollution, genetic factors, infection of HPV viruses and EBV (Epstein-Barr) virus \[[@pone.0159140.ref043]\], family history (immediate blood relatives within three generations), etc. In developed countries, tobacco and alcohol is a major factor \[[@pone.0159140.ref042]--[@pone.0159140.ref044]\]. However, it is different in countries with high incidence of EC, as few cases are attributed to smoking or alcohol consumption there \[[@pone.0159140.ref045]\].

Currently, the role of HPV infection in esophageal cancer is unclear. Many studies from Africa and China have shown that HPV infections were associated with esophageal cancer. However, in areas with lower prevalence of HPV, there was no decrease in risk of EC \[[@pone.0159140.ref046]--[@pone.0159140.ref049]\]. The differences in the results of the studies may be due to: 1. Differences in race, living habits, environmental factors that lead to HPV infection. 2. Differences in research design, detection means, methods, statistical analysis. The aim of this study was to perform a comprehensive analysis of the data to determine the relationship between EC and HPV.

In order to explain the association between HPV and EC, we reviewed many articles and selected only case-control studies for analysis. To our knowledge, this is the first study that conducted a systematic review of the relationship between HPV infection (types 16 and 18) and EC worldwide. Results of the comprehensive evaluation of this final systematic review revealed that there was a significant association between HPV infection and EC risk with an integrated OR = 1.62 (95% CI: 1.33--1.98). In META analysis, the presence or absence of heterogeneity directly affected the results of the statistics. Therefore, this study was conducted to strictly evaluate heterogeneity.

HPV infection rates may be related to geographical location. Therefore, we preformed a subgroup analysis according to geographical location worldwide. The stratification study revealed that regardless of whether the studies were in China, Asia, outside of China, or outside of Asia, or in high or low risk areas, HPV infection was associated with EC. In the current research, most studies from low-risk areas also had an association between HPV and EC, and these correlations were stronger than high-risk areas; which was different from other reports. A possible reason was that in high-risk areas, EC occurred due to other reasons such as eating habits, tobacco, alcohol, pollution, genetic factors and HPV infection; thus, the influence of HPV decreased \[[@pone.0159140.ref050]\]. In low-risk areas, HPV infection appears to be the main cause.

Although most of the esophageal cancer risk factors have been determined, there may still be unknown confounders that may interfere with the results. The literature included case-control studies that were inevitably affected by a variety of bias.

However, due to the current study design, many kinds of bias were possible. (1) Most studies detected HPV from tumor tissues and tissues around tumors that could have been infected with HPV. (2) This systematic review included many studies from all over the world. The variable HPV prevalence could have been related to the various geographic regions studied.

The choice of the control group may have also affected the results, because the healthy controls group revealed that HPV was associated more closely with EC. Cancer adjacent tissues as controls also confirmed a link between HPV and EC, but with a weaker correlation than the cancer tissue itself. This may be related to the HPV infection of the cancer tissue in the body or contamination of samples. There are many methods for detecting HPV, and there was no uniform detection method used in these studies. The researchers did not make use the same HPV detection methods used such as PCR, ELISA, ISH and IHC; although some of the early HPV detection techniques have since been abandoned. Therefore, these results are likely to have some bias, and PCR seems to be the most accurate monitoring method \[[@pone.0159140.ref051]\].

The current result was the same as that reported by Zhang et al. \[[@pone.0159140.ref048],[@pone.0159140.ref052]\] except that their study was limited to a Chinese population, and used a PCR detection method for HPV16. Zhang et al. found that there was a relatively high level of HPV 16 prevalence in Chinese patients with esophageal cancer, and concluded that HPV-16 infection may be a risk factor for esophageal cancer. The current research included the entire world population, and all methods to detect HPV16. Using a subgroup analysis, we obtained results similar to those of Zhang et al. While, there was the limitation that the analyses did not distinguish between the two primary histologic forms of esophageal cancer: squamous cell carcinoma and adenocarcinoma. From our research, squamous cell carcinoma were more likely linked to HPV, adenocarcinoma was fewer than squamous cell carcinoma. This may be related to its biological characteristics.

Conclusions {#sec020}
===========

These results indicate that HPV is closely associated with EC in China, Asia, and all over the world. In investigating the association between HPV and EC, the selection of the control group is important in order to avoid interfering factors. This systematic review provides epidemiologic evidence to support the association between HPV infection and EC. Multi-center studies on regional incidences with strict control of false positives and false negatives would be needed to confirm the association of HPV and EC. If confirmed, HPV testing may be useful in groups at high risk for EC; while HPV vaccine might be useful as a primary prevention measure.
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HPV

:   human papillomavirus

EC

:   esophageal carcinoma

RR

:   risk ratio

CIs

:   confidence intervals

PCR

:   polymerase chain reaction

ISH

:   *in situ* hybridization

ICH

:   immunohistochemistry

ELISA

:   enzyme-linked immunosorbent assay

FEM

:   fixed effects model

REM

:   random effects model

OR

:   odds ratio

EBV

:   Epstein-Barr
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